PHARMACEUTICAL INDUSTRIES

Intestinal Biotech Development is screening many promising molecules at the early stage of development for pharmaceutical industry clients who are focused on this field of pathology.

For about a decade, solid progress has been observed in the treatment of inflammatory bowel diseases. New strategies, and advanced technology therapies with monoclonal antibodies, have been established, but some unmet medical needs still remain. More ambitious and demanding research for the patient’s benefits, new therapeutic targets, and innovative medicines are goals for the pharmaceutical industry.

No single compound solves all the problems

For a long time, many compounds have been used in the treatment of IBD, such as corticosteroids, immunosuppressant agents, and 5 ASA, but none of them alone or in association could solve all the problems caused by the disease. Nevertheless, much progress has been observed for around a decade in the treatment of digestive tract diseases including the inflammatory bowel diseases. New strategies have been established, and advanced technology therapies with “biologics” - particularly monoclonal antibodies like anti-TNFα – have been launched into the market. But unmet medical needs remain.

More ambitious research is needed

More ambitious and demanding research for the patient’s benefits, new therapeutic targets, and innovative medicines are still the goal for every researcher around the world. On the other hand, nutrition and gut health are major concerns for a large population. Some food ingredients appear to have interesting properties to improve the intestinal comfort in functional disturbances, including pain. These fields need to be explored with specific ingredients.
Strong arguments have indicated that this process involves the intestinal flora and emphasized the role of nutrition. Therefore, identifying new markers – new targets – is crucial, not only to find out how to treat patients with inflammatory bowel diseases like Crohn’s Disease or ulcerative colitis, by novel compounds, but also to enhance the gut health in the general population with food ingredients.